Abstract: Sustained delivery formulations comprising a water-insoluble complex of a peptide and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptide of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.
Type:
Grant
Filed:
July 8, 1999
Date of Patent:
March 2, 2004
Assignee:
Praecis Pharmaceuticals, Inc.
Inventors:
Malcolm L. Gefter, Nicholas Barker, Gary Musso, Christopher J. Molineaux
Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.
Abstract: A substantially pure polypeptide (human NESP55) comprising the amino acid sequence
(SEQ ID NO: 2)
IRLEVPKRMDRRSRAQQWRRARHNYNDLCPPIGRRAATALLWLSCSIALL
RALATSNARAQQRAAAQQRRSFLNAHHRSGAQVFPESPESESDHEHEEAD
LELSLPECLEYEEEFDYETESETESEIESETDFETEPETAPTTEPETEPE
DDRGPVVPKHSTFGQSLTQRLHALKLRSPDASPSRAPPSTQEPQSPREGE
ELKPEDKDPRRDPEESKEPKEEKQRRRCKPKKPTRRDASPESPSKKGPIP
IRRH
or a variant, fragment, fusion or derivative thereof, or a fusion of a said variant or fragment or derivative, wherein the polypeptide variant has an amino acid sequence which has at least 90% identity with the amino acid sequence given above.
NESP55 or fragments thereof may be useful in medicine for the treatment of obesity.
Abstract: A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
July 8, 2003
Assignee:
Abbott Laboratories
Inventors:
William H. Harclerode, Robert Gault, Mark D. Sandison
Abstract: Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.
Type:
Grant
Filed:
October 20, 2000
Date of Patent:
April 15, 2003
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Kenneth G. Carson, David Thomas Connor, Jie Jack Li, Joseph Edwin Low, Jay R. Luly, Steven Robert Miller, Bruce David Roth, Bharat Kalidas Trivedi
Abstract: The present invention relates to isolated MEKK proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to use such proteins to regulate signal transduction in a cell. The present invention also includes therapeutic compositions comprising such proteins or nucleic acid molecules that encode such proteins and their use to treat animals having medical disorders including cancer, inflammation, neurological disorders, autoimmune diseases, allergic reactions, and hormone-related diseases. When MEKK is expressed, it phosphorylates and activates MKKs 1-4 (also referred to as MEK-1, MEK-2 and JNKK1 and JNKK2).
Type:
Grant
Filed:
April 5, 1996
Date of Patent:
December 25, 2001
Assignee:
National Jewish Center for Immunology and Respiratory
Medicine